- United Kingdom
- /
- Medical Equipment
- /
- AIM:EKF
EKF Diagnostics Holdings First Half 2025 Earnings: EPS: UK£0.004 (vs UK£0.005 in 1H 2024)
EKF Diagnostics Holdings (LON:EKF) First Half 2025 Results
Key Financial Results
- Revenue: UK£25.2m (flat on 1H 2024).
- Net income: UK£1.94m (down 5.9% from 1H 2024).
- Profit margin: 7.7% (down from 8.2% in 1H 2024).
- EPS: UK£0.004 (down from UK£0.005 in 1H 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
EKF Diagnostics Holdings Earnings Insights
Looking ahead, revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in the United Kingdom.
Performance of the British Medical Equipment industry.
The company's shares are up 2.4% from a week ago.
Risk Analysis
You should learn about the 1 warning sign we've spotted with EKF Diagnostics Holdings.
Valuation is complex, but we're here to simplify it.
Discover if EKF Diagnostics Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:EKF
EKF Diagnostics Holdings
Engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally.
Flawless balance sheet and undervalued.
Market Insights
Community Narratives


